Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04698421
Other study ID # RC31/20/0150
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 12, 2020
Est. completion date September 3, 2030

Study information

Verified date July 2023
Source University Hospital, Toulouse
Contact Chloé Bost, PharmD, PhD
Phone 5 61 77 61 44
Email bost.c@chu-toulouse.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.


Description:

Neuroimmunology is a rapidly expanding field since major advances have been made in basic immunology and numerous new clinical entities have been identified in the last 10 years. Even if these discoveries have led to major advances in patient's management and treatment, a lot of work needs to be done to improve the diagnosis and prognostic biomarkers. It is widely known that the immune system is implicated in a variety of neurological disorders such as infections, encephalitis or multiple sclerosis. Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system and need to be recognized as some of them can be cured by appropriate immunotherapy. These neurological disorders include autoimmune encephalitis and paraneoplastic neurological syndromes but also myasthenia, chronic demyelinating inflammatory polyneuropathy and other neuromuscular pathologies. These neurological disorders are characterized by the presence of autoantibodies in the patient's sera or cerebral spinal fluid (CSF). These autoantibodies are generally highly specific and necessary to make the diagnosis. However, in some cases, despite strong clinical arguments for a neuroimmunological disorder, we do not identify autoantibodies, leading to inappropriate treatment and a blind follow-up considering the risk of recurrence or of associated tumor. Furthermore, even if the specific role of some autoantibodies or of immune T cells in some of these pathologies are suspected or already documented, for most of them the exact mechanism is still unknown. We need to explore the sera and CSF of these patients to identify new diagnosis and prognosis biomarker. Moreover, the availability of immune cells isolated from these patients will help us to decipher the pathophysiological mechanisms to create new therapeutic strategies. For this, animal models are already available in Centre Physiopathology Toulouse and in the French reference center in Lyon. As genetic susceptibilities may underlie, at least in part, the variability of the clinical manifestations and of the response to treatment, DNA from patients will be collected and immune genes sequencing will be compared to other control groups, included international database.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date September 3, 2030
Est. primary completion date January 1, 2030
Accepts healthy volunteers No
Gender All
Age group 6 Years to 99 Years
Eligibility Inclusion Criteria: - all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and/or central nervous system symptoms. - Social coverage up to date. Exclusion Criteria: - Patients with neurological damage from which the autoimmune character can be excluded. - Known anemia and hemoglobin <10 g / dl - Patients under protective supervision (guardianship, curators) - Pregnant or breastfeeding woman

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood collection on admission and longitudinally
Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).

Locations

Country Name City State
France Purpan University Hospital Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Building a collection of biological samples and clinical-biological data from patients with rare autoimmune neurological diseases Blood sampling Day 0 and through study completion, an average of 1 year
Secondary Identification of new autoantibodies. ELISA Day 0 and through study completion, an average of 1 year
Secondary Identification of biomarkers regarding the severity (such as cytokines, axonal damages...) in order to help the therapeutic decisions. Analysis of the phenotypic profiling of blood immune cells by multicolor fluorescence-activated cell sorter (FACS) analysis and of the transcriptomic profiling of blood immune cells by RNA sequencing Day 0 and through study completion, an average of 1 year
Secondary Exploration of the pathophysiological mechanisms of rare autoimmune neurological pathologies. Knock-out or knock-in animal models for one specific protein will be used to determine in vivo if the pathophysiological mechanisms of rare autoimmune neurological disorder can be induced by the abnormal expression of this protein. Day 0 and through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT03336645 - Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan Phase 3
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Not yet recruiting NCT06048523 - Prospective Cohort Study of Neurogenetic Diseases N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Active, not recruiting NCT02284126 - Topical Vancomycin for Neurosurgery Wound Prophylaxis Phase 3
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT00739518 - Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams N/A
Recruiting NCT03678194 - Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application N/A
Recruiting NCT06111898 - Neuro-biomechanical Determinants for Motor Behavior in High-risk Infants